Rare Disease (hATTR)
Time to Act! Hereditary ATTR Amyloidosis Polyneuropathy: Early Diagnosis and Treatment
Hereditary transthyretin amyloidosis polyneuropathy (hATTR PN) is a rare, inherited, multisystemic, rapidly progressing and life-threatening debilitating disease caused by mutations in the TTR gene.
This program addresses the signs and symptoms, key diagnostic assessments and treatments for ATTR PN available in Canada.
Upon completion of this continuing education program, participants will be better able to:
-
Review the neurological presentation of hereditary transthyretin amyloidosis polyneuropathy (hATTR PN);
-
Describe the key assessments that may lead to a diagnosis of hATTR PN;
-
Discuss the treatment options specific to polyneuropathy and determine when they are most appropriate for hATTR PN.
Planning Committee
Steven Baker, MD, MSc, FRCPC
Hamilton, ON
Vera Bril, MSc, MD, FRCPC
Toronto, ON
Amanda Fiander, MD, FRCPC
Halifax, NS
This activity is an Accredited Self-Assessment Program (Section 3) as defined by the Maintenance of Certification Program of The Royal College of Physicians & Surgeons of Canada, and approved by McMaster University, Continuing Professional Development Office (CPD) for a maximum of 1 MOC Section 3 hour.
This initiative has been sponsored in part by Alnylam Canada through an educational grant.